TY - JOUR
T1 - 18 F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas
T2 - a cross-sectional study
AU - Patel, Chirag B.
AU - Fazzari, Elisa
AU - Chakhoyan, Ararat
AU - Yao, Jingwen
AU - Raymond, Catalina
AU - Nguyen, Huytram
AU - Manoukian, Jasmine
AU - Nguyen, Nhung
AU - Pope, Whitney
AU - Cloughesy, Timothy F.
AU - Nghiemphu, Phioanh L.
AU - Czernin, Johannes
AU - Lai, Albert
AU - Ellingson, Benjamin M.
N1 - Publisher Copyright:
© 2018, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2018/9/1
Y1 - 2018/9/1
N2 - Introduction: To report the potential value of pre-operative 18 F-FDOPA PET and anatomic MRI in diagnosis and prognosis of glioma patients. Methods: Forty-five patients with a pathological diagnosis of glioma with pre-operative 18 F-FDOPA PET and anatomic MRI were retrospectively examined. The volume of contrast enhancement and T2 hyperintensity on MRI images along with the ratio of maximum 18 F-FDOPA SUV in tumor to normal tissue (T/N SUV max ) were measured and used to predict tumor grade, molecular status, and overall survival (OS). Results: A significant correlation was observed between WHO grade and: the volume of contrast enhancement (r = 0.67), volume of T2 hyperintensity (r = 0.42), and 18 F-FDOPA uptake (r = 0.60) (P < 0.01 for each correlation). The volume of contrast enhancement and 18 F-FDOPA T/N SUV max were significantly higher in glioblastoma (WHO IV) compared with lower grade gliomas (WHO I–III), as well as for high-grade gliomas (WHO III–IV) compared with low-grade gliomas (WHO I–II). Receiver-operator characteristic (ROC) analyses confirmed the volume of contrast enhancement and 18 F-FDOPA T/N SUV max could each differentiate patient groups. No significant differences in 18 F-FDOPA uptake were observed by IDH or MGMT status. Multivariable Cox regression suggested age (HR 1.16, P = 0.0001) and continuous measures of 18 F-FDOPA PET T/N SUV max (HR 4.43, P = 0.016) were significant prognostic factors for OS in WHO I–IV gliomas. Conclusions: Current findings suggest a potential role for the use of pre-operative 18 F-FDOPA PET in suspected glioma. Increased 18 F-FDOPA uptake may not only predict higher glioma grade, but also worse OS.
AB - Introduction: To report the potential value of pre-operative 18 F-FDOPA PET and anatomic MRI in diagnosis and prognosis of glioma patients. Methods: Forty-five patients with a pathological diagnosis of glioma with pre-operative 18 F-FDOPA PET and anatomic MRI were retrospectively examined. The volume of contrast enhancement and T2 hyperintensity on MRI images along with the ratio of maximum 18 F-FDOPA SUV in tumor to normal tissue (T/N SUV max ) were measured and used to predict tumor grade, molecular status, and overall survival (OS). Results: A significant correlation was observed between WHO grade and: the volume of contrast enhancement (r = 0.67), volume of T2 hyperintensity (r = 0.42), and 18 F-FDOPA uptake (r = 0.60) (P < 0.01 for each correlation). The volume of contrast enhancement and 18 F-FDOPA T/N SUV max were significantly higher in glioblastoma (WHO IV) compared with lower grade gliomas (WHO I–III), as well as for high-grade gliomas (WHO III–IV) compared with low-grade gliomas (WHO I–II). Receiver-operator characteristic (ROC) analyses confirmed the volume of contrast enhancement and 18 F-FDOPA T/N SUV max could each differentiate patient groups. No significant differences in 18 F-FDOPA uptake were observed by IDH or MGMT status. Multivariable Cox regression suggested age (HR 1.16, P = 0.0001) and continuous measures of 18 F-FDOPA PET T/N SUV max (HR 4.43, P = 0.016) were significant prognostic factors for OS in WHO I–IV gliomas. Conclusions: Current findings suggest a potential role for the use of pre-operative 18 F-FDOPA PET in suspected glioma. Increased 18 F-FDOPA uptake may not only predict higher glioma grade, but also worse OS.
KW - F-FDOPA PET
KW - Biomarker
KW - Glioma
KW - MRI
UR - http://www.scopus.com/inward/record.url?scp=85045759779&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045759779&partnerID=8YFLogxK
U2 - 10.1007/s11060-018-2877-6
DO - 10.1007/s11060-018-2877-6
M3 - Article
C2 - 29679199
AN - SCOPUS:85045759779
SN - 0167-594X
VL - 139
SP - 399
EP - 409
JO - Journal of neuro-oncology
JF - Journal of neuro-oncology
IS - 2
ER -